NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free MOR Stock Alerts $17.51 +0.10 (+0.57%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$17.21▼$17.7150-Day Range$17.36▼$18.1852-Week Range$4.18▼$18.31Volume502,740 shsAverage Volume1.70 million shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$11.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get MorphoSys alerts: Email Address MorphoSys MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside32.7% Downside$11.78 Price TargetShort InterestHealthy1.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.18Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.08) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.53 out of 5 starsMedical Sector859th out of 927 stocksPharmaceutical Preparations Industry393rd out of 415 stocks 1.2 Analyst's Opinion Consensus RatingMorphoSys has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphoSys has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.02% of the outstanding shares of MorphoSys have been sold short.Short Interest Ratio / Days to CoverMorphoSys has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MorphoSys has recently decreased by 6.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphoSys does not currently pay a dividend.Dividend GrowthMorphoSys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOR. Previous Next 2.1 News and Social Media Coverage News SentimentMorphoSys has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for MorphoSys this week, compared to 3 articles on an average week.Search Interest2 people have searched for MOR on MarketBeat in the last 30 days. MarketBeat Follows3 people have added MorphoSys to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MorphoSys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of MorphoSys is held by insiders.Percentage Held by InstitutionsOnly 18.38% of the stock of MorphoSys is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MorphoSys are expected to grow in the coming year, from ($2.08) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MorphoSys is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MorphoSys is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphoSys has a P/B Ratio of 50.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About MorphoSys Stock (NASDAQ:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesApril 29, 2024 | msn.comMorphoSys reports Q1 resultsApril 29, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports First Quarter 2024 Financial ResultsMay 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 29, 2024 | uk.investing.comMorphosys says takeover by Novartis on course after report of drug safety concernApril 29, 2024 | benzinga.comMorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, PelabresibApril 29, 2024 | reuters.comMorphosys says Novartis takeover progressing as planned for H1 2024April 28, 2024 | markets.businessinsider.comHere's what to expect from Morphosys's earningsApril 27, 2024 | msn.comGermany stocks higher at close of trade; DAX up 1.39%May 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 23, 2024 | ca.finance.yahoo.comNovartis lifts guidance after Q1 results beat expectationsApril 23, 2024 | uk.finance.yahoo.comNovartis raises guidance after beating Q1 expectationsApril 11, 2024 | markets.businessinsider.comEQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | markets.businessinsider.comMorphoSys Recommends Shareholders Accept Offer By Novartis - Quick FactsApril 11, 2024 | finance.yahoo.comMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | businesswire.comMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisApril 11, 2024 | finanznachrichten.deAspermont Limited: Aspermont is Announcing 'Future of Mining Perth': Unveiling Innovations, Sustainability, and Industry Growth!April 11, 2024 | reuters.comNovartis begins tender offer for MorphoSysApril 11, 2024 | globenewswire.comNovartis tender offer for MorphoSys AG commencesMarch 20, 2024 | investing.comMorphoSys AG ADR (MOR)March 16, 2024 | seekingalpha.comMorphoSys AG (MOR) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | uk.investing.comEarnings call: MorphoSys reported a strong performance for 2023March 16, 2024 | ca.finance.yahoo.comNVS Apr 2024 80.000 callMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement ProspectsMarch 14, 2024 | msn.comBiotech Rally Gets $100 Billion M&A Lift With More Deals to ComeMarch 13, 2024 | businesswire.comMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | finance.yahoo.comEltaMD Establishes March 13th as National Dermatologist Day, Building a Healthier Future for AllMarch 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from Morphosys's earningsSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/01/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MOR CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees524Year FoundedN/APrice Target and Rating Average Stock Price Target$11.78 High Stock Price Target$18.25 Low Stock Price Target$4.75 Potential Upside/Downside-32.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,350,000.00 Net Margins-226.79% Pretax Margin-80.13% Return on Equity-10,108.30% Return on Assets-21.85% Debt Debt-to-Equity Ratio4.98 Current Ratio3.08 Quick Ratio2.84 Sales & Book Value Annual Sales$257.89 million Price / Sales10.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book50.03Miscellaneous Outstanding Shares150,620,000Free Float150,546,000Market Cap$2.64 billion OptionableNot Optionable Beta1.17 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.91MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $764.53kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $513.54kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXMerusNASDAQ:MRUSACADIA PharmaceuticalsNASDAQ:ACADSummit TherapeuticsNASDAQ:SMMTPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 18,413 shares on 5/1/2024Ownership: 0.022%Hennion & Walsh Asset Management Inc.Bought 48,710 shares on 4/17/2024Ownership: 0.078%Virtu Financial LLCBought 24,640 shares on 2/26/2024Ownership: 0.016%Opaleye Management Inc.Sold 1,064,380 shares on 2/15/2024Ownership: 0.096%Kynam Capital Management LPBought 4,234,685 shares on 2/14/2024Ownership: 2.811%View All Institutional Transactions MOR Stock Analysis - Frequently Asked Questions Should I buy or sell MorphoSys stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares. View MOR analyst ratings or view top-rated stocks. What is MorphoSys' stock price target for 2024? 8 Wall Street analysts have issued 12-month price objectives for MorphoSys' shares. Their MOR share price targets range from $4.75 to $18.25. On average, they predict the company's stock price to reach $11.78 in the next year. This suggests that the stock has a possible downside of 32.7%. View analysts price targets for MOR or view top-rated stocks among Wall Street analysts. How have MOR shares performed in 2024? MorphoSys' stock was trading at $9.90 on January 1st, 2024. Since then, MOR shares have increased by 76.9% and is now trading at $17.51. View the best growth stocks for 2024 here. Are investors shorting MorphoSys? MorphoSys saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,630,000 shares, a drop of 22.0% from the March 15th total of 2,090,000 shares. Based on an average daily volume of 2,010,000 shares, the short-interest ratio is currently 0.8 days. View MorphoSys' Short Interest. When is MorphoSys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our MOR earnings forecast. How were MorphoSys' earnings last quarter? MorphoSys AG (NASDAQ:MOR) announced its earnings results on Wednesday, March, 13th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $1.25. The business earned $63.53 million during the quarter, compared to the consensus estimate of $76.30 million. MorphoSys had a negative trailing twelve-month return on equity of 10,108.30% and a negative net margin of 226.79%. What ETFs hold MorphoSys' stock? ETFs with the largest weight of MorphoSys (NASDAQ:MOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What is Simon E. Moroney's approval rating as MorphoSys' CEO? 5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. Who are MorphoSys' major shareholders? MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.08%) and BNP Paribas Financial Markets (0.02%). How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MOR) was last updated on 5/2/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
